NCT01311505已完成1 期
An Open Label, Single Dose, Randomized, Two-Way Cross-Over Bioequivalence Study Comparing Rifampicin In A Fixed-Dose Combination Rifampicin + Isoniazid (Myrin© 2, Pfizer Inc) Tablet With The Reference Drug (Rimactane®, Novartis Sandoz) Capsule In Healthy Filipino Male Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 21
- 试验地点
- 1
- 主要终点
- Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC [0-t])
研究概览
简要总结
This study is done to demonstrate bioequivalence of rifampicin component in Myrin© 2 Fixed-Dose Combination Tablet (each contains 75 mg isoniazid and 150 mg rifampicin, Pfizer Inc) with equivalent dose of the reference Rimactane® capsule (each contains 300 mg rifampicin, Novartis Sandoz) in healthy Filipino male subjects. This study also aims to determine the safety and tolerability of Myrin© 2 tablets and Rimactane® capsules in these subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy male subjects between the ages of 18 and 55 years, inclusive.
- •Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).
- •An informed consent document signed and dated by the subject.
- •Subjects willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
排除标准
- •Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
- •Any condition possibly affecting drug absorption (e.g., gastrectomy).
- •A positive urine drug screen.
- •History of regular alcohol consumption exceeding 21 drinks/week (1 drink = 5 ounces (150 ml) of wine or 12 ounces (360 ml) of beer or 1.5 ounces (45 ml) of hard liquor) within 6 months of screening.
- •Treatment with an investigational drug within 3 months (or as determined by the local requirement, whichever is longer) or 5 half-lives preceding the first dose of study medication.
- •12-lead ECG demonstrating QTc >450 msec at screening. If QTc exceeds 450 msec, the ECG should be repeated two more times and the average of the three QTc values should be used to determine the subject's eligibility.
- •History of previous treatment for TB or is suspected of suffering from TB.
- •Use of prescription or nonprescription drugs and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication. Herbal medication, herbal supplements and hormone replacement therapy must be discontinued 28 days prior to the first dose of study medication. As an exception, acetaminophen / paracetamol may be used at doses of less than 1 g/day. Limited use of non-prescription medications that are not believed to affect subject safety or the overall results of the study may be permitted on a case-by-case basis following approval by the sponsor.
- •Blood donation of approximately 1 pint (500 ml) within 56 days prior to dosing.
- •A history of hypersensitivity to any of the study medications or related substances, or to any of the ingredients used in the study drug formulations.
- •Unwilling or unable to comply with the Lifestyle guidelines described in this protocol.
- •Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
- •Recent history of diarrhea (2 weeks).
- •Recent use of oral (2 weeks) or IV (2-3 months) antibiotics to assure normal bowel flora at study start.
研究组 & 干预措施
A
Active Comparator
Test
干预措施: Myrin© 2 (Rifampicin + Isoniazid) (Drug)
B
Active Comparator
Reference
干预措施: Rimactane® (Rifampicin) (Drug)
结局指标
主要结局
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC [0-t])
时间窗: 0 (pre-dose), 1, 2, 3, 4, 6, 8 and 10 hours (hrs) post-dose
AUC (0-t)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t)
Maximum Observed Plasma Concentration (Cmax)
时间窗: 0 (pre-dose), 1, 2, 3, 4, 6, 8 and 10 hrs post-dose
次要结局
- Time to Reach Maximum Observed Plasma Concentration (Tmax)(0 (pre-dose), 1, 2, 3, 4, 6, 8 and 10 hrs post-dose)
- Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0-∞])(0 (pre-dose), 1, 2, 3, 4, 6, 8 and 10 hrs post-dose)
- Plasma Decay Half-life (t1/2)(0 (pre-dose), 1, 2, 3, 4, 6, 8 and 10 hrs post-dose)
- Extrapolated Area Under the Curve (AUC Percent [%] Extrapolated)(0 (pre-dose), 1, 2, 3, 4, 6, 8 and 10 hrs post-dose)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Bioequivalence Study Comparing A Fixed Dose Combination Formulation Of Myrin P Forte That Contains Rifampicin, Isoniazid, Ethambutol And Pyrazinamide Per Tablet To An Equivalent Dose Of Single Drug Reference Preparations Of Similar Combination Following Oral Administration In Healthy AdultsHealthy VolunteersNCT01399788Pfizer36
已完成
不适用
Bioequivalency Study of Ramipril 10 mg Capsules Under Fed ConditionsHypertensionNCT00702260Roxane Laboratories39
已完成
不适用
Bioequivalency Study of Terbinafine Tablets Under Fasting ConditionsOnychomycosisNCT00602342Roxane Laboratories30
已完成
不适用
Bioequivalency Study of Terbinafine Tablets Under Fed ConditionsOnychomycosisNCT00602251Roxane Laboratories30
已完成
1 期
A Study to Determine the Bioequivalence of Alogliptin and Pioglitazone When Administered as Individual Tablets and as Fixed-Dose Combination (FDC)-SYR-322-4833 BL Tablets to Healthy Russian ParticipantsHealthy VolunteersNCT03501277Takeda72